SYRE
Spyre Therapeutics, Inc.
Key Financials
Revenue
$0
NaN%
Net Income
$-155203000
↑ 25.4%
Operating Income
$-209562000
↓ 0.5%
Total Assets
$777.8M
↑ 27.8%
EPS (Diluted)
$-49.12
↓ 4861.6%
Total Liabilities
$62.5M
↓ 31.0%
Shareholders' Equity
$715.2M
↑ 38.1%
Cash & Equivalents
$85.7M
↓ 4.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 4 | 8/10/2026 | View on SEC |
| 144 | 8/7/2026 | View on SEC |
| 144 | 8/7/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 10-Q | 8/4/2026 | View on SEC |
| 144 | 8/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SYRE |
| Company Name | Spyre Therapeutics, Inc. |
| CIK | 1636282 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6176515940 |